Therapies market, valued at USD 16.7 million in 2024, is expected to register robust revenue CAGR of 44.6%.Request free copy of this report: 13, 2026- The growing incidence of autoimmune disorders ...
London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces ...
While presenting this year’s Nobel Prize in Physiology or Medicine to three immunologists who discovered and characterized regulatory T cells, committee chair Olle Kämpe, M.D., Ph.D., told the ...
The Chosun Ilbo on MSN
Sakaguchi: Cancer could become common disease within 20 years
Once an era arrives where cancer can be treated through immunity, cancer will no longer be a terrifying disease but an ...
TangGene names former GSK SVP Catherine Sohn as Senior Strategic Advisor, strengthening leadership as it advances a first-in-class in-vivo CD8⁺ Treg therapy. TangGene’s in-vivo CD8⁺ Treg approach has ...
CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options. CK0804, an investigational allogeneic regulatory T cell ...
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results